Telitacicept Improves Clinical Response in Active SLE
A 52-week trial published in the New England Journal of Medicine found that telitacicept produced a higher clinical response rate compared to placebo in patients with active systemic lupus erythematosus (SLE) receiving standard background therapy.
The study evaluated the efficacy and safety of telitacicept, a dual B-cell activating factor (BAFF) and APRIL inhibitor, and found that patients treated with telitacicept achieved significantly greater improvements in disease activity scores.
According to the study, telitacicept effectively suppresses B-cell overactivation, a key driver of autoimmunity in SLE, by targeting both BAFF and APRIL pathways.
However, the treatment was also linked to increased rates of upper respiratory infections, decreased immunoglobulin levels, and injection-site reactions, underscoring the need for careful monitoring.
Telitacicept’s mechanism effectively suppresses B-cell overactivation, a key driver of autoimmunity in SLE.
Author's summary: Telitacicept improves SLE response but increases infection risk.